Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS

Detalhes bibliográficos
Principais autores:	Cull, C, Wright, A, Holman, R, Grp, U
Formato:	Journal article
Publicado em:	2000

Registros relacionados

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
por: Matthews, DR, et al.
Publicado em: (1998)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
por: Matthews, DR, et al.
Publicado em: (1998)

Sulphonylurea therapy over six years does not delay progression to diabetes
por: Herlihy, O, et al.
Publicado em: (2000)

Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
por: Cull, C, et al.
Publicado em: (2001)

Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
por: Cull, C, et al.
Publicado em: (1999)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
por: Eeley, E, et al.
Publicado em: (1996)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
por: Wright, A, et al.
Publicado em: (2002)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
por: Turner, R, et al.
Publicado em: (1999)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
por: Turner, R, et al.
Publicado em: (1998)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
por: Cull, C, et al.
Publicado em: (1995)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
por: Eeley, E, et al.
Publicado em: (1996)

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
por: Wright, A, et al.
Publicado em: (2006)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
por: Turner, R, et al.
Publicado em: (1999)

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
por: Wright, A, et al.
Publicado em: (1998)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
por: Cull, C, et al.
Publicado em: (2004)

Ethnic differences in diabetic nephropathy - The UKPDS
por: Stevens, R, et al.
Publicado em: (1999)

UK PROSPECTIVE DIABETES STUDY (UKPDS) .10. URINARY ALBUMIN EXCRETION OVER 3 YEARS IN DIET-TREATED TYPE-2, (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS, AND ASSOCIATION WITH HYPERTENSION, HYPERGLYCEMIA AND HYPERTRIGLYCERIDEMIA
por: Cull, C, et al.
Publicado em: (1993)

Glucose control in UKPDS type 2 diabetic patients with and without autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase.
por: Mehta, Z, et al.
Publicado em: (1999)

Risk factors for incident albuminuria and renal dysfunction in the UKPDS
por: Adler, A, et al.
Publicado em: (2000)

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
por: Holman, R, et al.
Publicado em: (1987)

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)
por: Manley, SE, et al.
Publicado em: (2000)

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
por: Davis, T, et al.
Publicado em: (2001)

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
por: Turner, R, et al.
Publicado em: (1998)

UKPDS: Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects
por: Widjaja, A, et al.
Publicado em: (1996)

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
por: Bottazzo, G, et al.
Publicado em: (2005)

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
por: Adler, A, et al.
Publicado em: (2003)

UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.
por: Widjaja, A, et al.
Publicado em: (1997)

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).
por: Alva, M, et al.
Publicado em: (2014)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
por: Price, H, et al.
Publicado em: (2007)

The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results
por: Levy, J, et al.
Publicado em: (1993)

[The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results]
por: Levy, J, et al.
Publicado em: (1993)

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
por: Turner, R, et al.
Publicado em: (1991)

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
por: Davis, T, et al.
Publicado em: (2005)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
por: Misra, S, et al.
Publicado em: (2018)

Inaugural Conference: UKPDS Legacy and Precision Therapy for Type 2 Diabetes Mellitus
por: Rury Holman
Publicado em: (2022-09-01)

Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).
por: Adler, A, et al.
Publicado em: (2005)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
por: Holman, R
Publicado em: (2007)

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
por: Kohner, E, et al.
Publicado em: (2001)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
por: Rachman, J, et al.
Publicado em: (1996)

Reinforced healthy living advice over six years does not delay progression to diabetes
por: Dyson, P, et al.
Publicado em: (2000)